Fourth quarter 2025 revenues were $196.9 million, a 5% increase over Q4 2024. Full-year 2025 revenues reached $726.4 million, a 4% increase over 2024. EXPAREL net product sales hit a record high, growing 7% in Q4 2025 to $155.8 million and 5% for the full year to $575.1 million. Full-year GAAP net income was $7.0 million ($0.16 per share) in 2025, a significant improvement from a GAAP net loss of $99.6 million ($2.15 per share) in 2024. Adjusted EBITDA for full-year 2025 was $186.5 million, down from $223.9 million in 2024. The company repurchased 5.9 million shares of common stock for $150.0 million in 2025, with $150.0 million remaining on the authorization expiring December 31, 2026. Pacira ended Q4 2025 with $238.4 million in cash, cash equivalents, and available-for-sale investments. The 5x30 strategy contributed to over 2.5 million patients benefiting from products and achieving the highest gross margins in company history.